Evidence map›Paper›PMID 41558030›Full record

ArticleBlood advances2026

Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.

Christopher Fan, Tomo Hayase, Chia-Chi Chang, Israel K Glover, Ivonne I Flores, Lauren K McDaniel, Miriam R Ortega, Christopher A Sanchez, Rawan K El-Himri, Alexandria N Brown and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Christopher FanDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-7117-6885
Tomo HayaseDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Chia-Chi ChangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-0050-1705
Israel K GloverDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ivonne I FloresDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Lauren K McDanielDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0005-1698-6657
Miriam R OrtegaDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Christopher A SanchezDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Rawan K El-HimriDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Alexandria N BrownDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jennifer L KarmouchDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0000-9360-4898
Mohamed A JamalDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-3404-2535
Saira S AhmedDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0007-0520-1089
Taylor M HalseyDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-8601-9949
Yimei JinDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-7599-7042
Wen-Bin TsaiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-8210-5882
Rishika PrasadDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-6875-0954
Altai EnkhbayarDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0005-2743-6722
Aqsa MohammedDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0002-6241-9942
Maren SchmiesterDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-8713-572X
Ashish DamaniaDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0001-3158-2846
Nadim J AjamiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-3808-8576
Jennifer A WargoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Christine B PetersonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-3316-0468
Gabriela RondonDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.
Taha Al-JuhaishiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0003-7220-2314
Amin M AlousiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-2498-8573
Jeffrey J MolldremDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-1196-1715
Richard E ChamplinDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-4314-5037
Elizabeth J ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-3947-4126
Eric MartensDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI.
Cesar A AriasDepartment of Medicine, Weill Cornell Medical College, New York, NY.
Robert R JenqDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-5434-439X
Eiko HayaseDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-4824-8844

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractLower gastrointestinal graft-versus-host disease (LGI-GVHD) carries morbidity and mortality for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with critical contributions from the intestinal microbiome. In a retrospective cohort of metagenomic sequencing of stool from patients with allo-HSCT (N = 90), we found that a reduction in specific Parabacteroides and Bacteroides species around the time of engraftment contributes to LGI-GVHD risk. Given the known diverse carbohydrate-degrading functionality of these bacteria, we investigated gene abundances for carbohydrate-active enzymes (CAZymes) and found that Parabacteroides merdae, P distasonis, and Bacteroides ovatus abundances were significantly correlated with CAZymes in patients who did not develop LGI-GVHD compared with those who did. The specific gene abundances of xylosidase, which contribute to the degradation of xylose-containing polysaccharides, were significantly associated with a reduced risk of LGI-GVHD. All these findings show the importance of the carbohydrate-degrading functionality of putative beneficial bacteria in mediating risk of LGI-GVHD.

Indexed as

BacteriaCarbohydrate MetabolismFecesGastrointestinal DiseasesGastrointestinal MicrobiomeGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansIncidence

Identifiers

PMID41558030
PMCPMC12997297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.